

Distribution Rights Agreement for Tyvaso[®], a Treatment for Pulmonary Arterial Hypertension, in Japan

This material is an English translation of the press release issued on March 28, 2017 in Japanese, and the Japanese release is given priority regarding content and interpretation.

March 28, 2017

Mochida Pharmaceutical Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter called “Mochida”) announces today that Mochida and United Therapeutics Corporation (Headquarters: Silver Spring, MD, CEO: Martine Rothblatt, hereinafter called “United Therapeutics”) have signed an agreement for the exclusive distribution of Tyvaso[®], a treatment for pulmonary arterial hypertension (PAH), in Japan. Under this agreement, Mochida will be responsible for obtaining marketing authorization of Tyvaso[®] and will conduct necessary development actions.

Tyvaso[®] is an inhaled medicine for the treatment for PAH, which contains a synthetic prostacyclin analog, treprostinil, as the active ingredient and is delivered directly to pulmonary vascular beds after being aerosolized with an ultrasonic nebulizer. Tyvaso[®] is originated and developed by United Therapeutics as a PAH treatment, has been marketed in the United States since 2009 and has the largest share in the inhaled PAH medicine market. Unlike injection, Tyvaso[®] can be non-invasively administered, and patients can take Tyvaso[®] by themselves using a dedicated lightweight portable nebulizer.

PAH is characterized by elevated pulmonary artery pressure caused by certain conditions. It is an orphan refractory disease accompanied by symptoms such as dyspnea, fatiguability, palpitations and dizziness on exertion and causes heart failure as it progresses. The number of patients in Japan is estimated to be several thousands.

Mochida has distributed Treprost[®], a treprostinil injection for PAH licensed by United Therapeutics, since Mochida obtained the marketing authorization for this product in 2014. Mochida believes that the development and the distribution of Tyvaso[®] will provide additional therapeutic options for patients with PAH and contribute to improvement of their QOL.

This agreement will have only a minor impact on the financial results of Mochida for the near term.